However, with the recent publication of RCTs and non-randomized studies confirming on direct steps of medical improvement, results of radiographic studies were regarded to be less critical for decision making. The NIH said that as the anti-malarial medication did not harm patients in the analysis, testing demonstrated little research that it could profit patients hospitalized with COVID-19. Aims To evaluate the effectiveness and safe practices of hydroxychloroquine plus standard-of-care compared with SOC alone in adult patients with COVID-19. concerns about the potency of hydroxychloroquine had already started to emerge among frontline clinicians, and were verified as time passes by bigger studies that failed to show significant proof improvement among coronavirus patients. Initially, the antimalarial medication appeared encouraging, with small studies indicating it possessed some antiviral results to treat people with COVID-19.